Drugs / Commercialized IPV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04264598 Comparator | Aug → Dec 2017 | poliomyelitis | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Commercialized IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04264598 ↗ |
| Known as | Salk IPV | “The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.” NCT04264598 ↗ |
| Route | Intramuscular | “Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively” NCT04264598 ↗ |